Nath Bio-Genes (India) Limited

NSE:NATHBIOGEN India Agricultural Inputs
Market Cap
$30.81 Million
₹2.67 Billion INR
Market Cap Rank
#28568 Global
#1540 in India
Share Price
₹140.41
Change (1 day)
-2.68%
52-Week Range
₹138.73 - ₹234.84
All Time High
₹537.81
About

Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers fiber and oil seeds, including cotton and mustard; seeds for field crops, such as bajra, corn, paddy, wheat, and jowar; fruit seeds; and seeds for vegetables comprisi… Read more

Nath Bio-Genes (India) Limited (NATHBIOGEN) - Net Assets

Latest net assets as of September 2025: ₹6.80 Billion INR

Based on the latest financial reports, Nath Bio-Genes (India) Limited (NATHBIOGEN) has net assets worth ₹6.80 Billion INR as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹10.14 Billion) and total liabilities (₹3.34 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₹6.80 Billion
% of Total Assets 67.04%
Annual Growth Rate 22.57%
5-Year Change 5.07%
10-Year Change 431.22%
Growth Volatility 62.02

Nath Bio-Genes (India) Limited - Net Assets Trend (2012–2025)

This chart illustrates how Nath Bio-Genes (India) Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Nath Bio-Genes (India) Limited (2012–2025)

The table below shows the annual net assets of Nath Bio-Genes (India) Limited from 2012 to 2025.

Year Net Assets Change
2025-03-31 ₹6.44 Billion +5.65%
2024-03-31 ₹6.10 Billion +6.41%
2023-03-31 ₹5.73 Billion +5.76%
2022-03-31 ₹5.42 Billion -11.63%
2021-03-31 ₹6.13 Billion +9.98%
2020-03-31 ₹5.58 Billion +9.86%
2019-03-31 ₹5.08 Billion +8.17%
2018-03-31 ₹4.69 Billion +241.04%
2017-03-31 ₹1.38 Billion +13.42%
2016-03-31 ₹1.21 Billion +13.22%
2015-03-31 ₹1.07 Billion +31.01%
2014-03-31 ₹817.78 Million +42.29%
2013-03-31 ₹574.74 Million +25.69%
2012-03-31 ₹457.28 Million --

Equity Component Analysis

This analysis shows how different components contribute to Nath Bio-Genes (India) Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 3274.4% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Retained Earnings ₹4.76 Billion 73.91%
Common Stock ₹190.04 Million 2.95%
Other Comprehensive Income ₹156.10 Million 2.42%
Other Components ₹1.33 Billion 20.72%
Total Equity ₹6.44 Billion 100.00%

Nath Bio-Genes (India) Limited Competitors by Market Cap

The table below lists competitors of Nath Bio-Genes (India) Limited ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Nath Bio-Genes (India) Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 6,099,187,000 to 6,443,871,000, a change of 344,684,000 (5.7%).
  • Net income of 385,998,000 contributed positively to equity growth.
  • Dividend payments of 38,008,000 reduced retained earnings.
  • Other comprehensive income decreased equity by 3,305,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income ₹386.00 Million +5.99%
Dividends Paid ₹38.01 Million -0.59%
Other Comprehensive Income ₹-3.31 Million -0.05%
Other Changes ₹-1.00K -0.0%
Total Change ₹- 5.65%

Book Value vs Market Value Analysis

This analysis compares Nath Bio-Genes (India) Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.42x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 4.91x to 0.42x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2012-03-31 ₹28.57 ₹140.41 x
2013-03-31 ₹35.91 ₹140.41 x
2014-03-31 ₹51.10 ₹140.41 x
2015-03-31 ₹66.94 ₹140.41 x
2016-03-31 ₹75.80 ₹140.41 x
2017-03-31 ₹85.97 ₹140.41 x
2018-03-31 ₹276.18 ₹140.41 x
2019-03-31 ₹267.09 ₹140.41 x
2020-03-31 ₹293.42 ₹140.41 x
2021-03-31 ₹322.71 ₹140.41 x
2022-03-31 ₹285.19 ₹140.41 x
2023-03-31 ₹301.61 ₹140.41 x
2024-03-31 ₹320.94 ₹140.41 x
2025-03-31 ₹336.21 ₹140.41 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Nath Bio-Genes (India) Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 5.99%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 10.58%
  • • Asset Turnover: 0.36x
  • • Equity Multiplier: 1.59x
  • Recent ROE (5.99%) is below the historical average (11.12%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2012 20.12% 7.42% 1.03x 2.62x ₹46.28 Million
2013 20.44% 8.53% 0.87x 2.75x ₹59.98 Million
2014 29.72% 12.83% 1.00x 2.32x ₹161.26 Million
2015 23.71% 13.70% 0.82x 2.11x ₹146.84 Million
2016 11.68% 8.74% 0.61x 2.20x ₹20.37 Million
2017 11.83% 9.59% 0.59x 2.10x ₹25.24 Million
2018 6.27% 15.35% 0.34x 1.22x ₹-175.05 Million
2019 7.57% 16.67% 0.36x 1.27x ₹-123.25 Million
2020 9.05% 18.04% 0.38x 1.31x ₹-52.78 Million
2021 9.08% 18.11% 0.39x 1.29x ₹-56.66 Million
2022 -12.42% -24.19% 0.38x 1.37x ₹-1.22 Billion
2023 6.11% 11.62% 0.38x 1.38x ₹-223.06 Million
2024 6.50% 16.01% 0.28x 1.44x ₹-213.73 Million
2025 5.99% 10.58% 0.36x 1.59x ₹-258.39 Million

Industry Comparison

This section compares Nath Bio-Genes (India) Limited's net assets metrics with peer companies in the Agricultural Inputs industry.

Industry Context

  • Industry: Agricultural Inputs
  • Average net assets among peers: $5,218,771,854
  • Average return on equity (ROE) among peers: 9.44%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Nath Bio-Genes (India) Limited (NATHBIOGEN) ₹6.80 Billion 20.12% 0.49x $9.86 Million
Agro Phos India Limited (AGROPHOS) $520.47 Million 9.61% 1.50x $4.15 Million
Aries Agro Limited (ARIES) $1.81 Billion 7.52% 1.37x $31.60 Million
Astec LifeSciences Limited (ASTEC) $1.35 Billion 10.91% 1.68x $35.37 Million
Bayer Cropscience Limited (BAYERCROP) $17.56 Billion 17.95% 0.39x $984.78 Million
Best Agrolife Limited (BESTAGRO) $577.23 Million 0.02% 0.90x $20.16 Million
Bhagiradha Chemicals & Industries Limited (BHAGCHEM) $461.53 Million -6.95% 2.88x $102.33 Million
Bharat Rasayan Limited (BHARATRAS) $437.35 Million 13.47% 0.48x $65.75 Million
Bohra Industries Limited (BOHRAIND) $568.54 Million -4.53% 0.07x $2.29 Million
Bombay Super Hybrid Seeds Limited (BSHSL) $1.05 Billion 25.22% 1.12x $24.86 Million
Chambal Fertilizers & Chemicals Limited (CHAMBLFERT) $27.85 Billion 21.19% 4.00x $752.16 Million